Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30683839 | 0.95 | NPSR1 (0.34) | DGAT1CYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL6355124 | 0.93 | NPSR1 (0.33) | DGAT1CYP4F2CYP4A11CTSKUSP2 | |
| SCHEMBL27472725 | 0.90 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL4742520 | 0.89 | CYP4F2 (0.31) | DGAT1CYP4F2CYP4A11BTK | |
| SCHEMBL4825718 | 0.87 | NPSR1 (0.42) | DGAT1CYP4F2CYP4A11NPSR1BTK | |
| SCHEMBL7410851 | 0.87 | SMN1; SMN2 (0.39) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL27574308 | 0.86 | CYP4F2 (0.30) | CYP4F2CYP4A11 | |
| SCHEMBL15535385 | 0.85 | DGAT1 (0.34) | DGAT1CYP4F2CYP4A11NPSR1BTK | |
| SCHEMBL4829842 | 0.85 | NPSR1 (0.31) | DGAT1CYP4F2CYP4A11NPSR1BTK | |
| SCHEMBL22927449 | 0.84 | CYP4F2 (0.30) | CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110218230-B | Vitamin C coupled platinum complex, intermediate thereof, preparation method thereof, pharmaceutical composition and application | 天津谷堆生物医药科技有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20210023129-A1 | PLATINUM PRODRUG PERFLUOROARYL PEPTIDE CONJUGATES | NATIONAL INSTITUTES OF HEALTH | 2021-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023129-A1 | PLATINUM PRODRUG PERFLUOROARYL PEPTIDE CONJUGATES | PF4, SSTR4, FGFR4 | DGAT1 1308/4885CYP4F2 1461/4885CYP4A11 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.